Europe’s medicines regulator said on Friday its human medicines committee had recommended Eli Lilly’s diabetes drug Mounjaro also be approved as a weight-loss treatment.
Novo Nordisk on Friday announced that it is investing more than $6 billion to boost manufacturing capacity in its home country of Denmark to meet current and future demand for products targeting serious chronic diseases.
Neurocrine Biosciences on Thursday announced that two of its candidates—from separate partnerships with Xenon Pharmaceuticals and Takeda—failed their respective Phase II studies in focal onset seizures and major depressive disorder.
French drugmaker Valneva said on Friday the U.S. Food and Drug Administration (FDA) has approved its Chikungunya single-dose vaccine in individuals aged 18 and above.
Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product’s launch.
Novo Nordisk will discontinue its long-acting insulin treatment Levemir in the U.S. by the end of next year, the company announced Wednesday.
AstraZeneca raised its annual earnings forecast on Thursday, helped by strong demand for its cancer drugs, and moved to boost its pipeline in the booming anti-obesity market with a deal costing up to $2 billion.
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission’s decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horizon Therapeutics.
Bayer is looking to shake things up with some major company changes after reporting “not acceptable” cash flow for the third quarter on Wednesday.
In the third quarter, Gilead‘s growth in its HIV and oncology businesses was nearly completely offset by declining sales from its COVID-19 drug Veklury (remdesivir) and hepatitis C virus portfolio.
